{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:40:01Z","timestamp":1770226801536,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40122-021-00296-3","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T13:02:40Z","timestamp":1627390960000},"page":"1309-1330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4283-6936","authenticated-orcid":false,"given":"Carl H.","family":"G\u00f6bel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Heinze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Karstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mascha","family":"Morscheck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Cirkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qutyaba","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabih","family":"Halwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad-Hani","family":"Temsah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Ziemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegfried","family":"G\u00f6rg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"M\u00fcnte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2163-112X","authenticated-orcid":false,"given":"Hartmut","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"296_CR1","unstructured":"Johns Hopkins University Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. 2021. https:\/\/coronavirus.jhu.edu\/map.html. Accessed 14 June 2021"},{"key":"296_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.7150\/ijms.50873","volume":"18","author":"HQ Liu","year":"2021","unstructured":"Liu HQ, Yuan B, An YW, et al. Clinical characteristics and follow-up analysis of 324 discharged COVID-19 patients in Shenzhen during the recovery period. Int J Med Sci. 2021;18:347\u201355.","journal-title":"Int J Med Sci"},{"key":"296_CR3","doi-asserted-by":"publisher","unstructured":"Dixon BE, Wools-Kaloustian K, Fadel WF, et al. Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: results from a statewide epidemiological study. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.10.11.20210922.","DOI":"10.1101\/2020.10.11.20210922"},{"key":"296_CR4","unstructured":"World Health Organization. COVID-19 vaccine tracker and landscape. 2021. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines. Accessed 14 June 2021"},{"key":"296_CR5","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2\u2014preliminary report. N Engl J Med. 2020;383:1920\u201331.","journal-title":"N Engl J Med"},{"key":"296_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671\u201381.","journal-title":"Lancet"},{"key":"296_CR7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet. 2020;396:887\u201397.","journal-title":"Lancet"},{"key":"296_CR8","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"296_CR9","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet. 2021;396:1979\u201393.","journal-title":"Lancet"},{"key":"296_CR10","doi-asserted-by":"publisher","first-page":"100689","DOI":"10.1016\/j.eclinm.2020.100689","volume":"31","author":"P Tebas","year":"2021","unstructured":"Tebas P, Yang S, Boyer JD, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial. EClinicalMedicine. 2021;31:100689.","journal-title":"EClinicalMedicine"},{"key":"296_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect Dis. 2021;21:39\u201351.","journal-title":"Lancet Infect Dis"},{"key":"296_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","volume":"27","author":"JR Barrett","year":"2021","unstructured":"Barrett JR, Belij-Rammerstorfer S, Dold C, et al. Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;27:279\u201388.","journal-title":"Nat Med"},{"key":"296_CR13","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","volume":"397","author":"KRW Emary","year":"2021","unstructured":"Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351\u201362.","journal-title":"Lancet"},{"key":"296_CR14","unstructured":"European Medicines Agency. COVID-19 Vaccine AstraZeneca. 2021. Assessment report. Procedure No. EMEA\/H\/C\/005675\/0000. EMA\/94907\/2021:1\u2013181"},{"key":"296_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat Med. 2021;27:270\u20138.","journal-title":"Nat Med"},{"key":"296_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet. 2020;396:467\u201378.","journal-title":"Lancet"},{"key":"296_CR17","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S1473-3099(20)30773-8","volume":"21","author":"SH Hodgson","year":"2021","unstructured":"Hodgson SH, Mansatta K, Mallett G, et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21:e26\u201335.","journal-title":"Lancet Infect Dis"},{"key":"296_CR18","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384:1885\u201398.","journal-title":"N Engl J Med"},{"key":"296_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, SaC C, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99\u2013111.","journal-title":"Lancet"},{"key":"296_CR20","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881\u201391.","journal-title":"Lancet"},{"key":"296_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","volume":"397","author":"OJ Wouters","year":"2021","unstructured":"Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397:1023\u201334.","journal-title":"Lancet"},{"key":"296_CR22","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.3346\/jkms.2021.36.e107","volume":"36","author":"SH Kim","year":"2021","unstructured":"Kim SH, Wi YM, Yun SY, et al. Adverse events in healthcare workers after the first dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 vaccination: a single center experience. J Korean Med Sci. 2021;36:e107.","journal-title":"J Korean Med Sci"},{"key":"296_CR23","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092\u2013101.","journal-title":"N Engl J Med"},{"key":"296_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ajem.2021.03.040","volume":"47","author":"A Spadaro","year":"2021","unstructured":"Spadaro A, Scott KR, Koyfman A, et al. Cerebral venous thrombosis: diagnosis and management in the emergency department setting. Am J Emerg Med. 2021;47:24\u20139.","journal-title":"Am J Emerg Med"},{"key":"296_CR25","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"296_CR26","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.jsps.2020.08.024","volume":"28","author":"A Alnefaie","year":"2020","unstructured":"Alnefaie A, Albogami S. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. Saudi Pharm J. 2020;28:1333\u201352.","journal-title":"Saudi Pharm J"},{"key":"296_CR27","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1080\/15321819.2020.1865400","volume":"41","author":"MM Anwar","year":"2020","unstructured":"Anwar MM. Immunotherapies and COVID-19 related neurological manifestations: a comprehensive review article. J Immunoassay Immunochem. 2020;41:960\u201375.","journal-title":"J Immunoassay Immunochem"},{"key":"296_CR28","first-page":"252","volume":"77","author":"SG De Leon-Rodriguez","year":"2020","unstructured":"De Leon-Rodriguez SG, Hernandez-Rico B, Olmo-Vazquez GD, et al. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines. Bol Med Hosp Infant Mex. 2020;77:252\u201361.","journal-title":"Bol Med Hosp Infant Mex"},{"key":"296_CR29","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1177\/0333102420965140","volume":"40","author":"R Magdy","year":"2020","unstructured":"Magdy R, Hussein M, Ragaie C, et al. Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: a cross sectional study. Cephalalgia. 2020;40:1422\u201331.","journal-title":"Cephalalgia"},{"key":"296_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.7573\/dic.2020-5-1","volume":"9","author":"D Orsucci","year":"2020","unstructured":"Orsucci D, Ienco EC, Nocita G, et al. Neurological features of COVID-19 and their treatment: a review. Drugs Context. 2020;9:5\u20131. https:\/\/doi.org\/10.7573\/dic.2020-5-1.","journal-title":"Drugs Context"},{"key":"296_CR31","doi-asserted-by":"publisher","first-page":"628971","DOI":"10.3389\/fimmu.2020.628971","volume":"11","author":"S Schlickeiser","year":"2020","unstructured":"Schlickeiser S, Schwarz T, Steiner S, et al. Disease severity, fever, age, and sex correlate with SARS-CoV-2 neutralizing antibody responses. Front Immunol. 2020;11:628971.","journal-title":"Front Immunol"},{"key":"296_CR32","doi-asserted-by":"publisher","first-page":"607918","DOI":"10.3389\/fimmu.2020.607918","volume":"11","author":"S Steiner","year":"2020","unstructured":"Steiner S, Sotzny F, Bauer S, et al. HCoV- and SARS-CoV-2 cross-reactive T cells in CVID patients. Front Immunol. 2020;11:607918.","journal-title":"Front Immunol"},{"key":"296_CR33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021;21:637\u201346.","journal-title":"Lancet Infect Dis"},{"key":"296_CR34","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","volume":"397","author":"I Jones","year":"2021","unstructured":"Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397:642\u20133.","journal-title":"Lancet"},{"key":"296_CR35","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1\u20132a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384:1824\u201335.","journal-title":"N Engl J Med"},{"key":"296_CR36","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1038\/s41467-020-17972-1","volume":"11","author":"S Wu","year":"2020","unstructured":"Wu S, Zhong G, Zhang J, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11:4081.","journal-title":"Nat Commun"},{"key":"296_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"FC Zhu","year":"2020","unstructured":"Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479\u201388.","journal-title":"Lancet"},{"key":"296_CR38","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845\u201354.","journal-title":"Lancet"},{"issue":"192","key":"296_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/braincomms\/fcab169","volume":"3","author":"C G\u00f6bel","year":"2021","unstructured":"G\u00f6bel C, Heinze A, Karstedt S, et al. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun. 2021;3(192):1. https:\/\/doi.org\/10.1093\/braincomms\/fcab169.","journal-title":"Brain Commun"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-021-00296-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-021-00296-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-021-00296-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T16:44:59Z","timestamp":1636649099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-021-00296-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["296"],"URL":"https:\/\/doi.org\/10.1007\/s40122-021-00296-3","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"assertion":[{"value":"14 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}